Investor Relations

We are a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders. We improve compliance, absorption, and more with our proprietary drug delivery technology.

NASDAQLPCN
FormDescriptionDateFormat
EFFECTNotice from the SEC of registration effectivenessNov 23, 2020Open Notice from the SEC of registration effectiveness in HTML.Open Notice from the SEC of registration effectiveness in DOC file.Open Notice from the SEC of registration effectiveness in PDF file.Open Notice from the SEC of registration effectiveness in XLS file.
UPLOADCorrespondence from the SEC to the FilerNov 20, 2020Open Correspondence from the SEC to the Filer in HTML.Open Correspondence from the SEC to the Filer in DOC file.Open Correspondence from the SEC to the Filer in PDF file.Open Correspondence from the SEC to the Filer in XLS file.
CORRESPCorrespondence from the Filer to the SECNov 20, 2020Open Correspondence from the Filer to the SEC in HTML.Open Correspondence from the Filer to the SEC in DOC file.Open Correspondence from the Filer to the SEC in PDF file.Open Correspondence from the Filer to the SEC in XLS file.
SC 13GSchedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutionsFeb 25, 2020Open Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions in HTML.Open Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions in DOC file.Open Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions in PDF file.Open Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions in XLS file.
SC 13GSchedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutionsFeb 12, 2020Open Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions in HTML.Open Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions in DOC file.Open Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions in PDF file.Open Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions in XLS file.
SC 13GSchedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutionsFeb 6, 2020Open Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions in HTML.Open Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions in DOC file.Open Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions in PDF file.Open Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions in XLS file.
SC 13G/AAmendment to a previously filed SC 13GJan 14, 2020Open Amendment to a previously filed SC 13G in HTML.Open Amendment to a previously filed SC 13G in DOC file.Open Amendment to a previously filed SC 13G in PDF file.Open Amendment to a previously filed SC 13G in XLS file.